Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 890 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo and standard of care Clear all
Completed Phase 3 Interventional Results available

Extended Varenicline Treatment for Smoking Among Cancer Patients

NCT01756885
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Varenicline, Placebo, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 7, 2026, 4:03 PM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)

NCT05624749
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
ianalumab, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
15
States / cities
Anniston, Alabama • La Palma, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 7, 2026, 4:03 PM EDT
Terminated Not applicable Interventional Results available

Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232)

NCT01881932
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer
Interventions
Acupuncture using Seirin® needles, Sham Acupuncture using Park Sham placebo acupuncture device
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Oct 7, 2026, 4:03 PM EDT
Completed Phase 1 Interventional

Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

NCT05195918
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, Placebo 2 capsules + Nintedanib or Pirfenidone, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone
Combination Product
Lead sponsor
Hal Chapman
Other
Eligibility
40 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 7, 2026, 4:03 PM EDT
Not yet recruiting Not applicable Interventional

Psychosocial Interventions for Young Adults With Hip Pain

NCT04039386
View directory record Official record
Conditions
Hip Dysplasia, Hip Pain Chronic, Hip Osteoarthritis, Hip Arthritis, Psychosocial Problem
Interventions
Cell Phone Based Cognitive Based Therapy (Pacifica App), Control
Device · Other
Lead sponsor
Michael C Willey
Other
Eligibility
15 Years to 39 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 7, 2026, 4:03 PM EDT
Completed Not applicable Interventional Results available

Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection

NCT01235546
View directory record Official record
Conditions
Endometritis, Wound Infection, Abscess, Surgical Site Infection
Interventions
Azithromycin and standard of care, Placebo and standard of care
Drug
Lead sponsor
Alan Tita
Other
Eligibility
14 Years and older · Female only
Enrollment
2,013 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Jackson, Mississippi + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 7, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

NCT02872103
View directory record Official record
Conditions
Breast Cancer, Neutropenia
Interventions
F-627, Placebo
Drug
Lead sponsor
EVIVE Biotechnology
Industry
Eligibility
18 Years to 74 Years · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 7, 2026, 4:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

NCT02401542
View directory record Official record
Conditions
Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
Interventions
Vofatamab, Docetaxel, Placebo
Drug
Lead sponsor
Rainier Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Gilbert, Arizona • Goodyear, Arizona • Duarte, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 7, 2026, 4:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure

NCT04311697
View directory record Official record
Conditions
Critical COVID-19 With Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS), Corona Virus Infection, Acute Lung Injury
Interventions
Aviptadil by intravenous infusion + standard of care, Normal Saline Infusion + standard of care
Drug
Lead sponsor
APR Applied Pharma Research s.a.
Other
Eligibility
18 Years to 100 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Fullerton, California • Irvine, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 7, 2026, 4:03 PM EDT
Active, not recruiting Phase 2 Interventional

Mesenchymal Stromal Cells in Living Donor Kidney Transplantation

NCT03478215
View directory record Official record
Conditions
Renal Transplantation, Mesenchymal Stem Cells
Interventions
Mesenchymal Stromal Stem Cells (MSCs) Infusion, Normal Saline (Placebo) Infusion
Biological · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 7, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery

NCT02556918
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 7, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Metabolic Health in Individuals With Spinal Cord Injury (SCI)

NCT03204240
View directory record Official record
Conditions
Spinal Cord Injuries, Skeletal Muscle Atrophy, Metabolic Disease
Interventions
Neuromuscular electrical stimulation
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 7, 2026, 4:03 PM EDT
Not listed Phase 4 Interventional

Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)

NCT00794625
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Valproate, Risperidone, Placebo, Stimulant medication, Behavioral family counseling
Drug · Behavioral
Lead sponsor
Joseph Blader
NIH
Eligibility
6 Years to 12 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Glen Oaks, New York • Stony Brook, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 7, 2026, 4:03 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

NCT04553406
View directory record Official record
Conditions
Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Interventions
SPR720, Placebo, Open-label Standard of Care
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Altamonte Springs, Florida • Atlantis, Florida • Clearwater, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 7, 2026, 4:03 PM EDT
Completed Early Phase 1 Interventional Results available

Non-Opioid Pramipexole and Pain

NCT03842709
View directory record Official record
Conditions
Chronic Pain
Interventions
Pramipexole Oral Tablet, Placebo
Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 7, 2026, 4:03 PM EDT
Not listed Phase 2 Interventional

IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

NCT04933799
View directory record Official record
Conditions
COVID-19 Pneumonia
Interventions
PF-06650833, Matching Placebo
Drug
Lead sponsor
Giovanni Franchin, M.D, Ph.D
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 7, 2026, 4:03 PM EDT
Terminated Not applicable Interventional

The Comparison of Semiconductor Embedded Therapeutic Arm Sleeves for the Treatment of ECRB Tendinopathy

NCT06846593
View directory record Official record
Conditions
ECRB Tendinopathy
Interventions
Semiconductor Embedded Therapeutic Arm Sleeves, Placebo Arm Sleeves, Platelet-Rich Plasma with Adipose Stem Cell (PRP+ASC) Injections
Device · Other
Lead sponsor
INCREDIWEAR HOLDINGS, INC.
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 7, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

TXA in Spinal Fusion

NCT04272606
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Tranexamic Acid, Saline Solution, Visual Acuity Exam, 3 Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)
Drug · Diagnostic Test
Lead sponsor
Catherine R. Olinger
Other
Eligibility
18 Years to 90 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 7, 2026, 4:03 PM EDT
Active, not recruiting Phase 1 Interventional

Study to Evaluate the Safety of Colchicine

NCT05335148
View directory record Official record
Conditions
Radiation Therapy
Interventions
oral colchicine(0.6 mg) once a day
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Livingston, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 7, 2026, 4:03 PM EDT
Completed Not applicable Interventional Results available

Auricular Acupuncture in the Treatment of Obesity

NCT02269371
View directory record Official record
Conditions
Obesity
Interventions
Auricular Acupuncture, Sham Acupuncture
Other
Lead sponsor
Mike O'Callaghan Military Hospital
Federal
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 7, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

NCT04560998
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Peripheral Arterial Disease
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
88
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 7, 2026, 4:03 PM EDT
Recruiting Phase 3 Interventional

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

NCT06961214
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Depemokimab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
56
States / cities
Sheffield, Alabama • Aurora, Colorado • Brooksville, Florida + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 7, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Results available

Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers

NCT02378714
View directory record Official record
Conditions
Nicotine Dependence, Major Depressive Disorder
Interventions
Varenicline, BASC, Standard treatment
Drug · Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 7, 2026, 4:03 PM EDT
Terminated Phase 3 Interventional

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

NCT05636176
View directory record Official record
Conditions
Heart Failure
Interventions
Ziltivekimab, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
4,874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
172
States / cities
Alexander City, Alabama • Fairhope, Alabama • Huntsville, Alabama + 141 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 7, 2026, 4:03 PM EDT